ESLAW
Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. (ESLAW) is currently in a range/mixed trend, trading below both the 50-day and 200-day moving averages. RSI is at 41.1, with 1/3 trend checks passing.
ESLAW with MA50 and MA200
Key levels & signals
Estrella Immunopharma, Inc. (ESLAW) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $0.08, and 1 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 29.6% and below the 200-day moving average by 3.4%.
ESLAW currently has an RSI reading of 41.1, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.
This page is designed to help you quickly understand what the ESLAW chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical firm based in Emeryville, California, dedicated to advancing T-cell immunotherapies for various hematological malignancies and solid tumors within the United States. Its lead investigational treatments include EB103, currently undergoing preclinical assessment for diffuse large B-cell lymphoma, and EB104, which targets both diffuse large B-cell lymphoma and acute lymphocytic leukemia. The company also collaborates with Imugene Limited to develop solid tumor therapies, integrating Imugene's candidate CF33-CD19t with Estrella's EB103.
ESLAW shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about ESLAW
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.